Date: 2012-10-23
Type of information: Grant
Company: Vaccibody (Norway)
Investors: Norwegian Research Council (Norway)
Amount: €2 million
Funding type: grant
Planned used: Vaccibody was granted support for the development of a novel therapeutic vaccine against precancerous lesion of the cervix from the Norwegian Research Council’s BIA program. The project period is 4 years and encompasses the collaboration with both Norwegian and UK academic institutions.
Others:
Therapeutic area: Cancer - Oncology - Infectious diseases
